CN111772178A - 一种诺丽谷物胚芽酵素及其制备方法和应用 - Google Patents
一种诺丽谷物胚芽酵素及其制备方法和应用 Download PDFInfo
- Publication number
- CN111772178A CN111772178A CN202010633706.7A CN202010633706A CN111772178A CN 111772178 A CN111772178 A CN 111772178A CN 202010633706 A CN202010633706 A CN 202010633706A CN 111772178 A CN111772178 A CN 111772178A
- Authority
- CN
- China
- Prior art keywords
- parts
- noni
- mixture
- lactobacillus
- buckwheat
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 244000131360 Morinda citrifolia Species 0.000 title claims abstract description 54
- 235000017524 noni Nutrition 0.000 title claims abstract description 54
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 102000004190 Enzymes Human genes 0.000 title claims description 10
- 108090000790 Enzymes Proteins 0.000 title claims description 10
- 241000186660 Lactobacillus Species 0.000 claims abstract description 32
- 229940039696 lactobacillus Drugs 0.000 claims abstract description 32
- 235000013339 cereals Nutrition 0.000 claims abstract description 29
- 235000009419 Fagopyrum esculentum Nutrition 0.000 claims abstract description 27
- 239000000843 powder Substances 0.000 claims abstract description 19
- 240000008397 Ganoderma lucidum Species 0.000 claims abstract description 18
- 235000001637 Ganoderma lucidum Nutrition 0.000 claims abstract description 18
- 244000077995 Coix lacryma jobi Species 0.000 claims abstract description 15
- 240000002853 Nelumbo nucifera Species 0.000 claims abstract description 15
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims abstract description 15
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims abstract description 15
- 240000001417 Vigna umbellata Species 0.000 claims abstract description 15
- 235000011453 Vigna umbellata Nutrition 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 15
- 244000068988 Glycine max Species 0.000 claims abstract description 14
- 235000010469 Glycine max Nutrition 0.000 claims abstract description 14
- GXCLVBGFBYZDAG-UHFFFAOYSA-N N-[2-(1H-indol-3-yl)ethyl]-N-methylprop-2-en-1-amine Chemical compound CN(CCC1=CNC2=C1C=CC=C2)CC=C GXCLVBGFBYZDAG-UHFFFAOYSA-N 0.000 claims abstract description 14
- 238000000855 fermentation Methods 0.000 claims abstract description 14
- 230000004151 fermentation Effects 0.000 claims abstract description 14
- 235000021552 granulated sugar Nutrition 0.000 claims abstract description 13
- 235000012907 honey Nutrition 0.000 claims abstract description 13
- 240000008620 Fagopyrum esculentum Species 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims description 31
- 239000011259 mixed solution Substances 0.000 claims description 26
- 239000007788 liquid Substances 0.000 claims description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 18
- 238000001914 filtration Methods 0.000 claims description 12
- 238000002156 mixing Methods 0.000 claims description 12
- 239000000706 filtrate Substances 0.000 claims description 10
- 239000008213 purified water Substances 0.000 claims description 9
- 238000003756 stirring Methods 0.000 claims description 8
- 238000011081 inoculation Methods 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 238000002791 soaking Methods 0.000 claims description 5
- 238000005303 weighing Methods 0.000 claims description 5
- 238000001816 cooling Methods 0.000 claims description 3
- 235000013376 functional food Nutrition 0.000 claims description 3
- 235000013402 health food Nutrition 0.000 claims description 2
- 210000004369 blood Anatomy 0.000 abstract description 9
- 239000008280 blood Substances 0.000 abstract description 9
- 235000013305 food Nutrition 0.000 abstract description 7
- 230000036039 immunity Effects 0.000 abstract description 6
- 108090000765 processed proteins & peptides Proteins 0.000 abstract description 5
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- 230000003796 beauty Effects 0.000 abstract description 3
- 230000003213 activating effect Effects 0.000 abstract description 2
- 230000009286 beneficial effect Effects 0.000 abstract description 2
- 239000000796 flavoring agent Substances 0.000 abstract description 2
- 235000019634 flavors Nutrition 0.000 abstract description 2
- 102000004196 processed proteins & peptides Human genes 0.000 abstract description 2
- 230000001988 toxicity Effects 0.000 abstract 1
- 231100000419 toxicity Toxicity 0.000 abstract 1
- 241000219051 Fagopyrum Species 0.000 description 21
- 230000000694 effects Effects 0.000 description 14
- 210000000582 semen Anatomy 0.000 description 12
- 230000006870 function Effects 0.000 description 10
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 8
- 244000098338 Triticum aestivum Species 0.000 description 7
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 6
- 230000001580 bacterial effect Effects 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 206010028980 Neoplasm Diseases 0.000 description 5
- 239000000047 product Substances 0.000 description 5
- 235000018102 proteins Nutrition 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 108090000623 proteins and genes Proteins 0.000 description 5
- 206010020772 Hypertension Diseases 0.000 description 4
- BUGBHKTXTAQXES-UHFFFAOYSA-N Selenium Chemical compound [Se] BUGBHKTXTAQXES-UHFFFAOYSA-N 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 235000012000 cholesterol Nutrition 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 235000019197 fats Nutrition 0.000 description 4
- 235000016709 nutrition Nutrition 0.000 description 4
- 230000035764 nutrition Effects 0.000 description 4
- 229910052711 selenium Inorganic materials 0.000 description 4
- 239000011669 selenium Substances 0.000 description 4
- 208000024172 Cardiovascular disease Diseases 0.000 description 3
- 235000008898 Morinda citrifolia Nutrition 0.000 description 3
- 102000019197 Superoxide Dismutase Human genes 0.000 description 3
- 108010012715 Superoxide dismutase Proteins 0.000 description 3
- 235000019714 Triticale Nutrition 0.000 description 3
- 235000021307 Triticum Nutrition 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000000975 bioactive effect Effects 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000010438 heat treatment Methods 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 229910052742 iron Inorganic materials 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 238000001959 radiotherapy Methods 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 241000228158 x Triticosecale Species 0.000 description 3
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- 206010007247 Carbuncle Diseases 0.000 description 2
- 208000004232 Enteritis Diseases 0.000 description 2
- 241000222336 Ganoderma Species 0.000 description 2
- 206010019233 Headaches Diseases 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 239000004472 Lysine Substances 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000007443 Neurasthenia Diseases 0.000 description 2
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 2
- 208000002193 Pain Diseases 0.000 description 2
- 230000036528 appetite Effects 0.000 description 2
- 235000019789 appetite Nutrition 0.000 description 2
- 206010003549 asthenia Diseases 0.000 description 2
- 208000006673 asthma Diseases 0.000 description 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 2
- 230000036772 blood pressure Effects 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 206010016256 fatigue Diseases 0.000 description 2
- 231100000869 headache Toxicity 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 230000036407 pain Effects 0.000 description 2
- 229940126532 prescription medicine Drugs 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000002040 relaxant effect Effects 0.000 description 2
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 description 1
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 description 1
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 description 1
- 206010000087 Abdominal pain upper Diseases 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010003210 Arteriosclerosis Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010058019 Cancer Pain Diseases 0.000 description 1
- 206010008479 Chest Pain Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- 206010012335 Dependence Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 201000000297 Erysipelas Diseases 0.000 description 1
- 201000005569 Gout Diseases 0.000 description 1
- 206010019133 Hangover Diseases 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- 206010024453 Ligament sprain Diseases 0.000 description 1
- OYHQOLUKZRVURQ-HZJYTTRNSA-N Linoleic acid Chemical compound CCCCC\C=C/C\C=C/CCCCCCCC(O)=O OYHQOLUKZRVURQ-HZJYTTRNSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 208000019914 Mental Fatigue Diseases 0.000 description 1
- 241000218231 Moraceae Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 description 1
- 239000005642 Oleic acid Substances 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 108091005804 Peptidases Proteins 0.000 description 1
- 244000046052 Phaseolus vulgaris Species 0.000 description 1
- 235000010627 Phaseolus vulgaris Nutrition 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 108010073771 Soybean Proteins Proteins 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- 208000010040 Sprains and Strains Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 206010044302 Tracheitis Diseases 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 206010047700 Vomiting Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- 230000000172 allergic effect Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 208000011775 arteriosclerosis disease Diseases 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 230000014461 bone development Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000008344 brain blood flow Effects 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 210000000748 cardiovascular system Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 208000019902 chronic diarrheal disease Diseases 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 210000003792 cranial nerve Anatomy 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000003111 delayed effect Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 235000020776 essential amino acid Nutrition 0.000 description 1
- 239000003797 essential amino acid Substances 0.000 description 1
- 201000005577 familial hyperlipidemia Diseases 0.000 description 1
- 230000037406 food intake Effects 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 230000007661 gastrointestinal function Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 208000018997 giddiness Diseases 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000004217 heart function Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 201000001421 hyperglycemia Diseases 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 description 1
- 235000020778 linoleic acid Nutrition 0.000 description 1
- OYHQOLUKZRVURQ-IXWMQOLASA-N linoleic acid Natural products CCCCC\C=C/C\C=C\CCCCCCCC(O)=O OYHQOLUKZRVURQ-IXWMQOLASA-N 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 208000019423 liver disease Diseases 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000007227 lymph node tuberculosis Diseases 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002366 mineral element Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 235000021281 monounsaturated fatty acids Nutrition 0.000 description 1
- 201000000585 muscular atrophy Diseases 0.000 description 1
- 208000031225 myocardial ischemia Diseases 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- -1 oxygen free radical Chemical class 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 235000020777 polyunsaturated fatty acids Nutrition 0.000 description 1
- 230000002980 postoperative effect Effects 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 230000013777 protein digestion Effects 0.000 description 1
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000005493 rutin Nutrition 0.000 description 1
- IKGXIBQEEMLURG-BKUODXTLSA-N rutin Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@@H]1OC[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-BKUODXTLSA-N 0.000 description 1
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 1
- 229960004555 rutoside Drugs 0.000 description 1
- 230000009758 senescence Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 235000019710 soybean protein Nutrition 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000003437 trachea Anatomy 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 230000008673 vomiting Effects 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2400/00—Lactic or propionic acid bacteria
- A23V2400/11—Lactobacillus
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Health & Medical Sciences (AREA)
- Nutrition Science (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种诺丽谷物胚芽酵素及其制备方法和应用,属于保健食品技术领域。诺丽谷物胚芽酵素包括以下质量份数的原料:薏苡仁5~10份、红豆5~10份、莲子5~10份、黑麦芽5~10份、燕麦片5~10份、灵芝孢子粉3~5份、荞麦5~10份、砂糖8~10份、蜂蜜1.0~1.5份、大豆芽10~15份、诺丽果干片10~20份和乳酸杆菌2~3份。并公开了制备方法和应用,本发明制备的诺丽谷物胚芽酵素风味独特,富含小分子肽,有助于祛毒排毒,美容养颜,补血活血,延缓衰老,提高免疫力,并且发酵周期大大缩短。
Description
技术领域
本发明涉及保健食品技术领域,更具体的说是涉及一种诺丽谷物胚芽酵素及其制备方法和应用。
背景技术
酵素产品有调节人体新陈代谢,提高免疫力,排毒养颜,润肠通便等多种功效。特别适合于老年和亚健康人群服用。
日本和韩国的酵素口服液生产的特点是采用的原料多,多采用自然接种方法,自然发酵时间长,一般需要2~3年的时间,且发酵产物不能定向控制,口感不佳,这些因素都限制了诺丽果酵素产品的市场拓展。
如何充分利用诺丽果,配套更多的营养成分,并调节其口感,已成为保健功能食品领域的研究方向。
因此,如何提供一种诺丽谷物胚芽酵素及其制备方法和应用,改善口感、缩短发酵时间并丰富营养是本领域技术人员亟需解决的问题。
发明内容
有鉴于此,本发明提供了一种诺丽谷物胚芽酵素及其制备方法和应用。
为了实现上述目的,本发明采用如下技术方案:
一种诺丽谷物胚芽酵素,包括以下质量份数的原料:薏苡仁5~10份、红豆5~10份、莲子5~10份、黑麦芽5~10份、燕麦片5~10份、灵芝孢子粉3~5份、荞麦5~10份、砂糖8~10份、蜂蜜1.0~1.5份、桑葚5~10份、大豆芽10~15份、诺丽果干片10~20份和乳酸杆菌2~3份。
诺丽果干片:含有大量生物活性物质,尤其是大量含有的一种生物碱赛洛宁是维持机体细胞正常代谢、促使蛋白质发挥作用的重要成分,缺少赛洛宁便会发生各种疾病。赛洛宁对人体健康甚至生命延续具有重大的影响力,它可以促进人体细胞再生,并且可以令受损的细胞组织重新活跃起来,恢复活动能力,恢复状态。
此外,诺丽果及其发酵产物还具有下列功能:第一,能够调节人体的肠道消化功能,因此对于肠炎、胃溃疡、消化不良和便秘有改善作用。第二,对各种疼痛有止痛作用,如关节痛、痛风、痛经、胃痛、头痛、癌性疼痛等,都有一定的缓解作用。第三,具有消炎作用,对于肺炎、肠炎、妇科炎症和关节炎,能够减轻炎症。第四,增强人体免疫功能,预防疾病,包括过敏体质、易感冒体质、改善睡眠、抗氧化、延缓衰老、改善肺部不适、排毒瘦身、美容和滋阴壮阳等。
大豆芽:富含蛋白质,在乳酸杆菌作用下,将大分子的大豆蛋白质水解成由2到10个氨基酸组成的小分子片段。富含22种氨基酸,其中包含9种人体不能合成的必需氨基酸及小分子的蛋白质,发芽大豆中含有丰富的蛋白酶和其他生物活性物质,易被人体吸收,适合蛋白质消化吸收不佳的人群食用,如中老年人、手术后恢复期病人、肿瘤及放化疗病人、胃肠功能不佳者等。具有提高免疫力、增强体力、缓解疲劳、降三高等功效。
黑麦芽:富硒黑小麦,雅号叫做益寿麦。具高营养、高滋补、高免疫之功能而身价倍增。经检测证实:黑小麦中的蛋白质、脂肪、淀粉、干物质、18种氨基酸总量均高于普通小麦,人体必须而又不能合成的七种氨基酸都远高于优质小麦,如其中苏氨酸比普通小麦高35.56%,缬氨酸对比高66.07%;同时,对人体有利的各种矿质无素含量也很高,如铁、钾和钙比普通小麦分别高81.4%、72.4%和132.3%。发芽黑小麦中除了会生成一些生物活性物质外,突出的就是会合成大量的维生素E,对儿童骨骼发育,清除活性氧自由基,防病治病、美容延年具有重要作用。硒是人体健康很重要的元素素有生命元素之称,食品中缺少硒会引起肌肉萎缩、心血管和肝脏疾病等,硒在体内不仅能解毒还可以阻止癌细胞生长。
荞麦:荞麦是一种营养丰富又能预防心血管疾病的健康食品,荞麦中的蛋白质含量高达11%,尤其是在粮食中普遍缺乏的赖氨酸在荞麦中相当丰富,比小麦、大米高2.7倍。荞麦中的维生素B1、维生素B2也高于小麦。荞麦中所含的3%~4%的脂肪主要为单不饱和脂肪酸的油酸和多不饱和脂肪酸的亚油酸,它们可以起到降低血脂的作用,而且也是前列腺素和脑神经的重要成份,所以还有调节、增强生理机能和健脑的功能。
荞麦中还含有烟酸和芦丁,具有降低血脂和胆固醇的作用,是治疗高血压、心脏病的有效食物。荞麦中还含有较多的矿物质,特别是磷、铁和镁,这些物质可以维持人体心血管系统和造血系统的正常功荞麦蛋白质中含有丰富的赖氨酸成分,其铁、锰、锌等微量元素比一般谷物更丰富,具有很好的营养保健作用。此外,荞麦还有开胃宽肠,下气消积。治绞肠痧,肠胃积滞,慢性泄泻,噤口痢疾,赤游丹毒,痈疽发背,瘰疬,汤火灼伤,解酒等功效。
灵芝孢子粉:灵芝孢子粉具有以下功效:
治疗心血管疾病:灵芝孢子粉对人体具有降血脂,提高血液供氧能力,改善血液循环,尤其是改善人体心脑血液循环和外周血液循环的作用。可使冠心病、高血脂动脉硬化症、心搏功能弱、心律失常、心绞痛、心肌缺敌国症等病的症状得到缓解,可使眩晕、胸闷、气短、记忆力衰退等症状得到明显好转。
改善神经衰弱:灵芝孢子粉对神经衰弱效果最为显著,能改善睡眠,增进食欲,使头痛、头胀症状减轻或消失,记忆力逐渐增强,神疲、乏力现象消失,且无副作用反应,无瘾性出现。
医治慢性气管炎:灵芝孢子粉对机体具有抑制致喘物质释放,解痉,松弛气管平滑机,消除免疫过敏反应等作用,因此对支气管炎及哮喘有良好的治疗效果。
有效防治肿瘤:肿瘤病人服用灵芝孢子粉后肿块缩小,疼痛大为减轻,食量、体力增加,生存期延长。肿瘤病人化疗、放疗时配合使用灵芝,能使血色素、血细胞、红细胞的总数保持较高水平,能减轻化疗、放疗对机体的损害。
优选的:包括以下质量份数的原料:薏苡仁10份、红豆10份、莲子10份、黑麦芽5份、燕麦片10份、灵芝孢子粉5份、荞麦10份、砂糖10份、蜂蜜1.0份、大豆芽10份、诺丽果干片15份和乳酸杆菌3份。
本发明还提供了一种诺丽谷物胚芽酵素的制备方法,包括下列步骤:
(1)按上述的诺丽谷物胚芽酵素称取各个原料;并利用乳酸杆菌制备乳酸杆菌菌液,待用;
(2)分别将薏苡仁、红豆、莲子、荞麦以及诺丽果干片用纯净水浸泡5~6小时,待用;
(3)将浸泡后的薏苡仁、红豆、莲子、荞麦、诺丽果干片混合后再与黑麦芽、燕麦片、灵芝孢子粉、大豆芽混合,得混合物A;向混合物A中加入纯净水,置于85~95℃条件下搅拌2h,得混合物B,其中混合物A与纯净水的质量比为1:5;
(4)将混合物B过滤,滤液与砂糖、蜂蜜混合均匀,并加入适量的纯水得混合液C,其中混合液C与混合物A的质量比为5:1;
(5)接种:混合液C冷却后用乳酸杆菌菌液接种,得混合液D;
(6)发酵:混合液D经发酵、过滤,滤液即诺丽谷物胚芽酵素。
其中,过滤都是5层纱布过滤;可将混合液B转移至大缸或酒坛内,缸口覆盖8层纱布,置于干净无尘的室内进行发酵;步骤(5)乳酸杆菌制备为乳酸杆菌菌液后,与混合液C的体积比为(3~5):100。
优选的:步骤(1)所述乳酸杆菌菌液的浓度为108~12CFU/mL。
优选的:步骤(5)所述混合物C冷却至30~40℃。
优选的:步骤(6)所述发酵温度25~32℃,发酵时间15~20天。
本发明还提供了上述的诺丽谷物胚芽酵素在制备保健食品或功能食品中的应用。
经由上述的技术方案可知,与现有技术相比,本发明公开提供了一种诺丽谷物胚芽酵素及其制备方法和应用,取得的技术效果为制备的诺丽谷物胚芽酵素风味独特,富含小分子肽,有助于祛毒排毒,美容养颜,补血活血,延缓衰老,提高免疫力,并且发酵周期大大缩短。
具体实施方式
下面将结合本发明实施例中的技术方案进行清楚、完整地描述,显然,所描述的实施例仅仅是本发明一部分实施例,而不是全部的实施例。基于本发明中的实施例,本领域普通技术人员在没有做出创造性劳动前提下所获得的所有其他实施例,都属于本发明保护的范围。
本发明实施例公开了一种诺丽谷物胚芽酵素及其制备方法和应用。
所需原料均为市售采购,例如,乳酸杆菌采购自西安百川生物科技有限公司,对其来源不做限定,在此不再一一赘述;未提及的方法均为常规实验方法,乳酸杆菌的活化、培养方法依照产品说明书操作即可。
实施例1
一种诺丽谷物胚芽酵素,包括以下质量的原料:薏苡仁5g、红豆10g、莲子5g、黑麦芽10g、燕麦片5g、灵芝孢子粉3g、荞麦5g、砂糖10g、蜂蜜1.0g、大豆芽10g、诺丽果干片20g和乳酸杆菌2g。
制备方法,包括下列步骤:
(1)称取各个原料;并利用乳酸杆菌制备乳酸杆菌菌液,待用;
(2)分别将薏苡仁、红豆、莲子、荞麦以及诺丽果干片用纯净水浸泡5小时,待用;
(3)将浸泡后的薏苡仁、红豆、莲子、荞麦、诺丽果干片再和黑麦芽、燕麦片、灵芝孢子粉、大豆芽混合得混合物A,加入混合物A5倍质量的纯水,置于85℃条件下搅拌加热2h,得混合物B;
(4)将混合物B经5层纱布过滤,滤液再和砂糖、蜂蜜混合搅拌均匀,并加入适量的纯水得混合液C,其中混合液C与混合物A的质量比为5:1;
(5)接种:待混合液C冷却至30℃,用步骤(1)制备的乳酸杆菌菌液接种,其中步骤(1)所述菌液的浓度为108~12CFU/mL,得混合液D;
(6)发酵:将混合液D经25℃发酵15天、5层纱布过滤,收集滤液得到诺丽谷物胚芽酵素。
实施例2
一种诺丽谷物胚芽酵素,其特征在于,包括以下质量的原料:薏苡仁10g、红豆10g、莲子10g、黑麦芽5g、燕麦片10g、灵芝孢子粉5g、荞麦10g、砂糖10g、蜂蜜1.0g、大豆芽10g、诺丽果干片15g和乳酸杆菌3g。
制备方法,包括下列步骤:
(1)称取各个原料;并利用乳酸杆菌制备乳酸杆菌菌液,待用;
(2)分别将薏苡仁、红豆、莲子、荞麦以及诺丽果干片用纯净水浸泡5小时,待用;
(3)将浸泡后的薏苡仁、红豆、莲子、荞麦、诺丽果干片再和黑麦芽、燕麦片、灵芝孢子粉、大豆芽混合得混合物A,加入混合物A5倍质量的纯水,置于90℃条件下搅拌加热2h,得混合物B;
(4)将混合物B经5层纱布过滤,滤液再和砂糖、蜂蜜混合搅拌均匀,并加入适量的纯水得混合液C,其中混合液C与混合物A的质量比为5:1;
(5)接种:待混合液C冷却至35℃,用步骤(1)制备的乳酸杆菌菌液接种,其中步骤(1)所述菌液的浓度为108~12CFU/mL,得混合液D;
(6)发酵:将混合液D经28℃发酵18天、5层纱布过滤,收集滤液得到诺丽谷物胚芽酵素。
实施例3
一种诺丽谷物胚芽酵素,包括以下质量的原料:薏苡仁10g、红豆5g、莲子10g、黑麦芽5g、燕麦片10g、灵芝孢子粉5g、荞麦5g、砂糖8g、蜂蜜1.5g、大豆芽15g、诺丽果干片10g和乳酸杆菌3g。
制备方法,包括下列步骤:
(1)称取各个原料;并利用乳酸杆菌制备乳酸杆菌菌液,待用;
(2)将薏苡仁、红豆、莲子、荞麦以及诺丽果干片用纯净水浸泡6小时,待用;
(3)将浸泡后的薏苡仁、红豆、莲子、荞麦、诺丽果干片再和黑麦芽、燕麦片、灵芝孢子粉、大豆芽混合得混合物A,加入混合物A5倍质量的纯水,置于95℃条件下搅拌加热2h,得混合物B;
(4)将混合物B经5层纱布过滤,滤液再和砂糖、蜂蜜混合搅拌均匀,并加入适量的纯水得混合液C,其中混合液C与混合物A的质量比为5:1;
(5)接种:待混合液C冷却至40℃,用步骤(1)制备的乳酸杆菌菌液接种,其中步骤(1)所述菌液的浓度为108~12CFU/mL,得混合液D;
(6)发酵:将混合液D经32℃发酵20天、5层纱布过滤,收集滤液得到诺丽谷物胚芽酵素。
实验效果:
筛选40名服药剂量、病况接近的高胆固醇及高血压患者分2组,每组20人,第1组仅服用处方药物,实验期间不服用其他保健食品,第2组在正常服用处方药条件下,每日早和晚服用本发明实施例2制备的诺丽肽酵素各20毫升,连续服用90天,每个月测量两次,跟踪监测血压、总胆固醇含量、中性脂肪含量以及超氧化物歧化酶(SOD)活性。具体结果(取平均值)见表1。
表1试验结果
结果表明,本发明制备的酵素对于高血压人群服用有辅助降压作用;在脂质代谢方面,服用后降低了总胆固醇含量,明显提高了血液中的SOD活性。说明服用本发明实施例制备的诺丽肽酵素能够辅助降压、净化血液,并使血液中清除活性氧自由基的能力得到加强,减缓容颜衰老和器官衰老。
本说明书中各个实施例采用递进的方式描述,每个实施例重点说明的都是与其他实施例的不同之处,各个实施例之间相同相似部分互相参见即可。
对所公开的实施例的上述说明,使本领域专业技术人员能够实现或使用本发明。对这些实施例的多种修改对本领域的专业技术人员来说将是显而易见的,本文中所定义的一般原理可以在不脱离本发明的精神或范围的情况下,在其它实施例中实现。因此,本发明将不会被限制于本文所示的这些实施例,而是要符合与本文所公开的原理和新颖特点相一致的最宽的范围。
Claims (7)
1.一种诺丽谷物胚芽酵素,其特征在于,包括以下质量份数的原料:薏苡仁5~10份、红豆5~10份、莲子5~10份、黑麦芽5~10份、燕麦片5~10份、灵芝孢子粉3~5份、荞麦5~10份、砂糖8~10份、蜂蜜1.0~1.5份、大豆芽10~15份、诺丽果干片10~20份和乳酸杆菌2~3份。
2.如权利要求1所述的一种诺丽谷物胚芽酵素,其特征在于,包括以下质量份数的原料:薏苡仁10份、红豆10份、莲子10份、黑麦芽5份、燕麦片10份、灵芝孢子粉5份、荞麦10份、砂糖10份、蜂蜜1.0份、大豆芽10份、诺丽果干片15份和乳酸杆菌3份。
3.一种诺丽谷物胚芽酵素的制备方法,其特征在于,包括下列步骤:
(1)按照权利要求1或2所述的诺丽谷物胚芽酵素称取各个原料;并利用乳酸杆菌制备乳酸杆菌菌液,待用;
(2)分别将薏苡仁、红豆、莲子、荞麦以及诺丽果干片用纯净水浸泡5~6小时,待用;
(3)将浸泡后的薏苡仁、红豆、莲子、荞麦、诺丽果干片混合后再与黑麦芽、燕麦片、灵芝孢子粉、大豆芽混合,得混合物A;向混合物A中加入纯净水,置于85~95℃条件下搅拌2h,得混合物B,其中混合物A与纯净水的质量比为1:5;
(4)将混合物B过滤,滤液与砂糖、蜂蜜混合均匀,并加入适量的纯水得混合液C,其中混合液C与混合物A的质量比为5:1;
(5)接种:混合液C冷却后用乳酸杆菌菌液接种,得混合液D;
(6)发酵:混合液D经发酵、过滤,滤液即诺丽谷物胚芽酵素。
4.如权利要求3所述的诺丽谷物胚芽酵素的制备方法,其特征在于,步骤(1)所述乳酸杆菌菌液的浓度为108~12CFU/mL。
5.如权利要求3所述的诺丽谷物胚芽酵素的制备方法,其特征在于,步骤(5)所述混合物C冷却至30~40℃。
6.如权利要求3所述的诺丽谷物胚芽酵素的制备方法,其特征在于,步骤(6)所述发酵温度25~32℃,发酵时间15~20天。
7.一种权利要求1或2任一所述的诺丽谷物胚芽酵素在制备保健食品或功能食品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010633706.7A CN111772178A (zh) | 2020-07-02 | 2020-07-02 | 一种诺丽谷物胚芽酵素及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010633706.7A CN111772178A (zh) | 2020-07-02 | 2020-07-02 | 一种诺丽谷物胚芽酵素及其制备方法和应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN111772178A true CN111772178A (zh) | 2020-10-16 |
Family
ID=72758393
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010633706.7A Pending CN111772178A (zh) | 2020-07-02 | 2020-07-02 | 一种诺丽谷物胚芽酵素及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN111772178A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116459296A (zh) * | 2023-04-23 | 2023-07-21 | 广东省科学院生物与医学工程研究所 | 一种灵芝诺丽果益生菌丸剂的制备方法 |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146300A (zh) * | 2014-08-06 | 2014-11-19 | 河南钧鼎生物科技有限公司 | 复合诺丽果浆及其制备方法 |
CN105919113A (zh) * | 2016-07-04 | 2016-09-07 | 江南大学 | 一种微生物发酵制备灵豆酵素的方法 |
CN106387582A (zh) * | 2016-09-20 | 2017-02-15 | 江南大学 | 一种谷物类发酵制备酵素的方法 |
CN106962699A (zh) * | 2017-03-13 | 2017-07-21 | 南通蛇类治疗研究所 | 新型保健谷物饮料 |
CN111150056A (zh) * | 2020-01-03 | 2020-05-15 | 世界诺丽(山东)生物工程有限公司 | 一种诺丽肽酵素及其制备方法和应用 |
CN111184214A (zh) * | 2018-11-15 | 2020-05-22 | 王琼 | 酵素胶原蛋白杂粮果蔬即食代餐粥及其制作方法 |
CN113498834A (zh) * | 2021-07-08 | 2021-10-15 | 石家庄原动力工业技术有限公司 | 一种食药用菌发酵饮品的集成发酵的方法 |
-
2020
- 2020-07-02 CN CN202010633706.7A patent/CN111772178A/zh active Pending
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104146300A (zh) * | 2014-08-06 | 2014-11-19 | 河南钧鼎生物科技有限公司 | 复合诺丽果浆及其制备方法 |
CN105919113A (zh) * | 2016-07-04 | 2016-09-07 | 江南大学 | 一种微生物发酵制备灵豆酵素的方法 |
CN106387582A (zh) * | 2016-09-20 | 2017-02-15 | 江南大学 | 一种谷物类发酵制备酵素的方法 |
CN106962699A (zh) * | 2017-03-13 | 2017-07-21 | 南通蛇类治疗研究所 | 新型保健谷物饮料 |
CN111184214A (zh) * | 2018-11-15 | 2020-05-22 | 王琼 | 酵素胶原蛋白杂粮果蔬即食代餐粥及其制作方法 |
CN111150056A (zh) * | 2020-01-03 | 2020-05-15 | 世界诺丽(山东)生物工程有限公司 | 一种诺丽肽酵素及其制备方法和应用 |
CN113498834A (zh) * | 2021-07-08 | 2021-10-15 | 石家庄原动力工业技术有限公司 | 一种食药用菌发酵饮品的集成发酵的方法 |
Non-Patent Citations (1)
Title |
---|
索婧怡等: "食用酵素的研究及发展前景分析", 《食品与发酵工业》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN116459296A (zh) * | 2023-04-23 | 2023-07-21 | 广东省科学院生物与医学工程研究所 | 一种灵芝诺丽果益生菌丸剂的制备方法 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106798252B (zh) | 一种具有调理肠胃降血脂溶血栓功效的纳豆产品 | |
CN110338402A (zh) | 一种复合益生菌粉及其制备方法 | |
CN115074298A (zh) | 具有抗幽护胃和消食化积功效的益生菌组合物及其应用 | |
CN103766904A (zh) | 一种具有降脂、通便功能胶囊的制备及其应用 | |
CN111972659A (zh) | 一种关于奇亚籽山药的代餐粉 | |
CN1237910C (zh) | 营养全粉及其生产方法 | |
CN111000252A (zh) | 一种减脂且营养均衡的代餐食品及其制备方法 | |
CN111184214A (zh) | 酵素胶原蛋白杂粮果蔬即食代餐粥及其制作方法 | |
CN111374312A (zh) | 一种补充全面营养且易吸收的健康食品 | |
CN103468515A (zh) | 一种糙米灵芝酒及其酿制方法 | |
CN111772178A (zh) | 一种诺丽谷物胚芽酵素及其制备方法和应用 | |
CN111150056A (zh) | 一种诺丽肽酵素及其制备方法和应用 | |
CN107212392A (zh) | 一种全营养发酵养生食品及其制备方法 | |
KR20110118911A (ko) | 한약재를 이용한 유산균 곡물 발효 추출물 및 이의 제조방법 | |
CN110192571A (zh) | 一种红薯红豆薏米调制乳的制备方法 | |
CN115590069A (zh) | 一种含有豌豆肽的组合物及其制备方法和应用 | |
CN115517369A (zh) | 保护心脑血管、提高免疫力的复合蛋白多肽粉及制备方法 | |
CN114470084A (zh) | 环保高效防治罗非鱼白便的组合物及其制备方法和应用 | |
CN103478706A (zh) | 一种天然葛酵素及其制法 | |
CN111436618A (zh) | 百香果多肽组合物及其制备方法 | |
CN110547449A (zh) | 一种富含γ-氨基丁酸的新型酵素口服片的制备方法 | |
CN104013853B (zh) | 一种健肾补肾的组合物及其制备方法 | |
CN102626123A (zh) | 一种紫薯降血糖煎饼及其制备方法 | |
CN116898051A (zh) | 一种药食同源植物饮料的制备方法 | |
CN114424793A (zh) | 灵芝富硒牛蒡根发酵茶的制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information |
Inventor after: Fu Yanxiang Inventor after: Zhang Wenhui Inventor after: Wang Kuiming Inventor after: Qian Ke Inventor before: Fu Yanxiang Inventor before: Zhang Wenhui Inventor before: Wang Kuiming |
|
CB03 | Change of inventor or designer information | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20201016 |
|
RJ01 | Rejection of invention patent application after publication |